ProKidney to Join Morgan Stanley 22nd Annual Global Healthcare Conference

ProKidney Corp. (Nasdaq: PROK), a prominent biotech company specializing in advanced cell therapy for chronic kidney disease (CKD), announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. This event is scheduled to take place in New York, NY, from September 4-6, 2024. Senior executives from ProKidney will engage in a fireside chat on Thursday, September 5, 2024, at 7:00 a.m. ET. The session will be available via a live webcast, which can be accessed through the "Events" section under the Investor Relations tab on the ProKidney website.

For those unable to attend the live session, a replay of the webcast will be accessible for 90 days post-event. Additionally, ProKidney’s management team will conduct one-on-one meetings with investors during the conference. Interested parties are advised to contact their Morgan Stanley representative to arrange these meetings.

ProKidney Corp., established in 2015 based on a decade of research, is at the forefront of treating CKD with innovative cellular therapies. The company’s leading product candidate, rilparencel (also known as REACT®), is a pioneering autologous cellular therapy specifically designed to maintain kidney function in patients suffering from diabetes and advanced CKD. Rilparencel has garnered significant recognition, including Regenerative Medicine Advanced Therapy (RMAT) designation, and has received guidance from both the FDA and EMA, which supports its ongoing Phase 3 clinical trials.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!